AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 7:00AM
Business Wire
AVEO Oncology (Nasdaq: AVEO) today announced that Michael
Bailey, president and chief executive officer of AVEO, will present
at the H.C. Wainwright Global Life Sciences Conference, being held
virtually on March 9-10, 2021.
A replay of the pre-recorded presentation can be accessed on
Tuesday, March 9, 2021 in the investors section of the Company’s
website at www.aveooncology.com. A replay of the webcast will be
archived for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed
to delivering medicines that provide a better life for cancer
patients. AVEO’s strategy is to focus its resources toward
development and commercialization of its product candidates in
North America, while leveraging partnerships to support development
and commercialization in other geographies. AVEO’s lead candidate,
tivozanib, is approved as FOTIVDA® in the European Union and other
countries in the EUSA territory for the treatment of adult patients
with advanced renal cell carcinoma. Tivozanib is being studied in
the TIVO-3 trial, which is supporting a regulatory submission of
tivozanib in the U.S. seeking marketing approval as a treatment for
relapsed or refractory renal cell carcinoma. AVEO has previously
reported promising early clinical data on ficlatuzumab (anti-HGF
IgG1 mAb) in head and neck cancer, pancreatic cancer and acute
myeloid leukemia and is conducting a randomized Phase 2
confirmatory clinical trial of ficlatuzumab for the potential
treatment of head and neck cancer. AVEO’s pipeline of product
candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has
previously reported the acceptance of its investigational new drug
application in the U.S. for AV-380 and its initiation of a Phase 1
clinical trial for the potential treatment of cancer cachexia.
AVEO’s earlier-stage pipeline includes monoclonal antibodies in
oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353
(anti-Notch 3 mAb). AVEO is committed to creating an environment of
diversity and inclusion.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302005378/en/
AVEO Contact: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jul 2023 to Jul 2024